AbbVie's Upadacitinib Aces Another Arthritis Trial, But Safety Concerns Linger
Executive Summary
AbbVie says safety results for the JAK1 inhibitor upadacitinib in SELECT-MONOTHERAPY study were in line with the rheumatoid arthritis population, but some analysts are concerned about the drug's cardiovascular profile, especially compared with Pfizer's first-in-class Xeljanz.
You may also be interested in...
Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie
Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
More Phase III data for AbbVie's selective JAK1 inhibitor upadacitinib appear to back a potential best-in-class claim but eyes remain on safety after a death from pulmonary embolism.
AbbVie May Be Poised For An Oral RA Smack Down
Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.